|Bid||93.88 x 373700|
|Ask||94.00 x 1281100|
|Day's range||93.64 - 94.52|
|52-week range||72.96 - 94.52|
|Beta (3Y monthly)||N/A|
|PE ratio (TTM)||27.63|
|Earnings date||23 Jan 2018 - 29 Jan 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||88.59|
The independence that monetary policy makers have traditionally enjoyed from politicians is under threat worldwide as much as it is in the U.S., where Powell repeatedly runs into tweeted attacks from President Donald Trump. Central banks from Turkey to India are regularly under pressure and even the Bank of England and European Central Bank aren’t immune to attacks from elected critics.
Switzerland approved an overhaul of the corporate tax code, choosing to stay an attractive base for companies like Procter & Gamble, Vitol SA and Caterpillar Inc. even at the expense of a short-term drop in fiscal revenue. The outcome, approved by 66.4% of voters, ends years of wrangling and a failed attempt at an overhaul two years ago, ensures Switzerland remains a low tax domicile for companies and still is compliant with international rules.
The property is a reminder of a time when millionaires parking money in clandestine accounts made a beeline for Geneva. Although the city has largely recovered from the end of secrecy at banks, whose numbers have shrunk by a quarter, Geneva faces questions about its allure for international businesses and the world’s wealthy. It wasn’t the city of choice for the likes of Netflix Inc., Alibaba Group Holding Ltd. and Amazon.com Inc. to base their European operations. The city, surrounded by the Alps and the Jura mountains and with a view of Mont Blanc, still has its resplendent landmark hotels, but they don’t get the fillip they once did from rich Arab guests each summer. “Sometimes I have the sense that we’re not hungry enough,” said Thierry Lavalley, general manager of the lake-facing Grand Hotel Kempinski Geneve.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Erin Fox, director of the drug information service at the University of Utah, said that this is a stubborn problem. Last year, then-FDA commissioner Scott Gottlieb proposed a move to approve more suppliers, but even with lower barriers to entry, it might not make economic sense for companies to build an expensive factory, or revamp a crumbling one, to make very cheap drugs with a minuscule profit margin. As this Bloomberg Opinion column from last year concludes: There’s good reason hospitals were not in the drug business.
Based on Novartis AG's (VTX:NOVN) earnings update in December 2018, analyst consensus outlook appear pessimistic, with profits p...
Attractive stocks have exceptional fundamentals. In the case of Novartis AG (VTX:NOVN), there's is a highly-regarded dividend-paying company with a a great track record of delivering benchmark-beating performance. In theRead More...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! This article is for investors who would like to improveRead More...
(Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of ...
Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines..
Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines.
Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland's 20 largest listed companies, market operator SIX said on Tuesday. Information about any other changes to SMI and Switzerland's other indexes will be released later, the bourse said. Novartis last year announced the spin off of Alcon to the Basel drugmaker's shareholders in the first half of this year.
* European stocks inch up as trade talks loom * LVMH jumps, driving luxury stocks up * Apple, Boeing lift Wall Street ahead of Fed decision Jan 30 - Welcome to the home for real-time coverage of European ...
Novartis Chief Executive Vas Narasimhan said he will be ready to discuss the future of generics unit Sandoz following a revamp due to take 18 months, while still calling the business "an integral part" of the Swiss drugmaker. "We consider Sandoz an integral part of Novartis, we're focused on transforming the business, making it an autonomous entity over the next 18 months that is able to compete as an independent unit within Novartis," Narasimhan said on a call with analysts on Wednesday.
Novartis's 2019 sales and profit growth guidance disappointed investors seeking more from Chief Executive Vas Narasimhan's efforts to focus the Swiss drugmaker on high-tech medicines while shedding non-core assets. The company sees net sales growing by a low- to mid-single-digit percentage, with core operating income up by a mid-single-digit rate, Novartis said on Wednesday. Shares in the world's biggest prescription drugmaker had slipped 1.1 percent by 1305 GMT, lagging a 0.2 percent decline in the Stoxx European Health Care Index.
* European stocks inch up as trade talks loom * LVMH jumps, driving luxury stocks up * Lonza tumbles after sales miss, CEO retiring * Atos leads STOXX 600 after results Jan 30 - Welcome to the home for ...